Nikolaidis Eleftherios, Bolanos Nikolaos, Anagnostopoulos Dimitrios, Leivaditis Vasileios, Grapatsas Konstantinos, Koletsis Efstratios, Papatriantafyllou Athanasios, Panagiotopoulos Ioannis, Mulita Francesk, Baltayiannis Nikolaos, Dahm Manfred, Chatzimichalis Antonios
Department of Thoracic Surgery, "Metaxa" Cancer Hospital, Piraeus, Greece.
Department of Cardiothoracic and Vascular Surgery, Westpfal-Klinikum, Kaiserslautern, Germany.
Kardiochir Torakochirurgia Pol. 2023 Jun;20(2):105-110. doi: 10.5114/kitp.2023.129546. Epub 2023 Jul 26.
Lung cancer is one of the leading causes of cancer-related deaths worldwide. Superior vena cava syndrome (SVCS) is a rare but potentially life-threatening complication of lung cancer, occurring in approximately 5-10% of cases. There are difficulties in the process of surgical treatment of SVC infiltrated by lung tumors but the contribution of technological evolution and innovation is promising. At the same time, the amelioration of survival rates of patients subjected to surgical treatment is equally promising. The reported outcomes of surgical treatment for SVC invasion due to lung tumors vary depending on the extent of the tumor and the patient's overall health status. However, studies clearly suggest that surgical treatment can improve survival and quality of life in selected patients. The literature review showed that the surgical approach to lung cancer invading the SVC constitutes the most indispensable treatment which helps to achieve the long-term survival of patients.
肺癌是全球癌症相关死亡的主要原因之一。上腔静脉综合征（SVCS）是肺癌罕见但可能危及生命的并发症，约5%-10%的病例会出现。肺肿瘤侵犯上腔静脉的手术治疗过程存在困难，但技术发展和创新的作用前景乐观。同时，接受手术治疗患者的生存率改善同样前景乐观。报道的因肺肿瘤导致上腔静脉侵犯的手术治疗结果因肿瘤范围和患者整体健康状况而异。然而，研究明确表明，手术治疗可改善部分患者的生存率和生活质量。文献综述显示，手术治疗侵犯上腔静脉的肺癌是实现患者长期生存最不可或缺的治疗方法。
